Status:
COMPLETED
Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone
Lead Sponsor:
Pfizer
Conditions:
Schizophrenia
Psychotic Disorders
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
To assess the effect of risperidone 2 mg daily (QD) on the differential sensitivity of 2 spatial working memory tests (the GMLT and MDR) in non-agitated, drug-naive patients suffering from first-episo...
Eligibility Criteria
Inclusion
- Male or female, 18 to 50 years old, antipsychotic-naive, non-agitated patients diagnosed with first-episode schizophrenia or schizophreniform disorder.
Exclusion
- Evidence or history of clinically significant medical or non-medical impairment that, in the opinion of the investigator, would affect the safety of the patient or interfere with the evaluation of the trial results;
- Patients who have a history of substance (which included alcohol) dependence within 12 months or abuse within 3 months of enrollment, or tested positive for an illicit drug on the Screening urine toxicology test
- Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00174200
Start Date
December 1 2004
End Date
May 1 2006
Last Update
July 15 2008
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Dartmouth, Nova Scotia, Canada, B2Y 3Z9
2
Pfizer Investigational Site
Halifax, Nova Scotia, Canada, B3H 2E2
3
Pfizer Investigational Site
Moscow, Russia, 107076